| Title | Withdrawal of Approval of Drug Application: Celgene Corporation and Teva Pharmaceutical Industries, Ltd.; Peripheral T-Cell Lymphoma Indication for ISTODAX (Romidepsin) for Injection and Romidepsin Injection |
| ToC Doc | Celgene Corporation and Teva Pharmaceutical Industries, Ltd.; Peripheral T-Cell Lymphoma Indication for ISTODAX (Romidepsin) for Injection and Romidepsin Injection |
| Docket Number | 2022-09889 |
| Type | Notice |
| Subject | Withdrawal of Approval of Drug Application: Celgene Corporation and Teva Pharmaceutical Industries, Ltd.; Peripheral T-Cell Lymphoma Indication for ISTODAX (Romidepsin) for Injection and Romidepsin Injection |
| Publication Date | 2022-05-09 |
| Last Updated Date | 2022-05-06 08:15:10 -0400 |
| Last Public Inspection | 2022-05-06 |
| Filed At | 2022-05-06T08:45:00.000-04:00 |
| 2022-09889_PI.pdf (59810 bytes) | |
| Download | TXT / HTML / JSON |
| Number of Pages | 3 |
| Filing Type | regular |
| Agencies | Food and Drug Administration |
You can find the raw source document below...